Blockade of na+ channels in pancreatic α-cells has antidiabetic effects

Diabetes

Volumn 63, Issue 10, 2014, Pages 3545-3556

  Dhalla, Arvinder K ^a   Yang, Ming ^a   Ning, Yun ^a   Kahlig, Kristopher M ^a   Krause, Michael ^a   Rajamani, Sridharan ^a   Belardinelli, Luiz ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLUCAGON; GLUCOSE; GS 458967; HEMOGLOBIN A1C; INSULIN; RANOLAZINE; SITAGLIPTIN; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHANNEL NAV1.3; SODIUM CHANNEL NAV1.6; SODIUM CHANNEL NAV1.7; UNCLASSIFIED DRUG; VERATIDINE; VERATRIDINE; ACETANILIDE DERIVATIVE; PIPERAZINE DERIVATIVE;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ELECTRIC ACTIVITY; GENE EXPRESSION; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PANCREAS ISLET ALPHA CELL; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; DRUG EFFECT; EXOCYTOSIS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PANCREAS ISLET; SPRAGUE DAWLEY RAT;

ACETANILIDES; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; EXOCYTOSIS; GLUCAGON; GLUCAGON-SECRETING CELLS; HUMANS; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; MALE; NAV1.3 VOLTAGE-GATED SODIUM CHANNEL; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHANNEL BLOCKERS;

EID: 84907481814     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1562     Document Type: Article

References (39)

1. Linger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975;1:14-16
2. Müller WA, Faloona GR, Linger RH. Hyperglucagonemia in diabetic keto-acidosis. Its prevalence and significance. Am J Med 1973;54:52-57
3. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nono bese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987;64:106-110
4. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of sup-pression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85:4053-4059
5. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 1995;38:337-343
6. Christensen M, Bagger JI, Vilsbøll T, Knop FK. The alpha-cell as target for type 2 diabetes therapy. Rev Diabet Stud 2011;8:369-381
7. Edgerton DS, Cherrington AD. Glucagon as a critical factor in the pathology of diabetes. Diabetes 2011;60:377-380
8. Göpel SO, Kanno T, Barg S, Weng XG, Gromada J, Rorsman P. Regulation of glucagon release in mouse -cells by KATP channels and inactivation of TTX-sensitive Na+ channels. J Physiol 2000;528:509-520
9. Vignali S, Leiss V, Karl R, Hofmann F, Welling A. Characterization of voltage-dependent sodium and calcium channels in mouse pancreatic A- and B-cells. J Physiol 2006;572:691-706
10. Ramracheya R, Ward C, Shigeto M, et al. Membrane potential-dependent inactivation of voltage-gated ion channels in alpha-cells inhibits glucagon secretion from human islets. Diabetes 2010;59:2198-2208
11. Huang YC, Rupnik MS, Karimian N, et al. In situ electrophysiological examination of pancreatic α cells in the streptozotocin-induced diabetes model, revealing the cellular basis of glucagon hypersecretion. Diabetes 2013;62:519-530
12. Chaitman BR, Skettino SL, Parker JO, et al.; MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-1382
13. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006;92(Suppl. 4):iv6-iv14
14. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42-48
15. Morrow DA, Scirica BM, Chaitman BR, et al.; MERLIN-TIMI 36 Investigators. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009;119:2032-2039
16. Chisholm JW, Goldfine AB, Dhalla AK, et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care 2010;33:1163-1168
17. Chisholm JW, Ning Y, Van Petten M, et al. Ranolazine treatment delays the development of diabetes in ZDF rats through B-cell preservation. Late-breaking abstract presented at the 71st Annual Meeting of the American Diabetes Association, 24-28 June 2011, at the San Diego Convention Center, San Diego, California
18. Ning Y, Zhen W, Fu Z, et al. Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. J Pharmacol Exp Ther 2011;337:50-58
19. Belardinelli L, Liu G, Smith-Maxwell C, et al. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J Pharmacol Exp Ther 2013;344:23-32
20. Dellê H, Saito MH, Yoshimoto PM, Noronha IL. The use of iodixanol for the purification of rat pancreatic islets. Transplant Proc 2007;39:467-469
21. Herrera PL. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. Development 2000;127:2317-2322
22. Barg S, Galvanovskis J, Göpel SO, Rorsman P, Eliasson L. Tight coupling between electrical activity and exocytosis in mouse glucagon-secreting alpha-cells. Diabetes 2000;49:1500-1510
23. MacDonald PE, De Marinis YZ, Ramracheya R, et al. A K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biol 2007;5:e143
24. Le Marchand SJ, Piston DW. Glucose decouples intracellular Ca2+ activity from glucagon secretion in mouse pancreatic islet alpha-cells. PLoS One 2012;7: e47084
25. Zhang Q, Ramracheya R, Bengtsson M, Braun M, Welling A, Rorsman P. Scn3a encodes the functionally important Na+-channel alpha-subunit (Nav 1.3) in mouse pancreatic alpha and beta cells. Diabetologia 2012;55:S204
26. Hirakawa R, El-Bizri N, Shryock JC, Belardinelli L, Rajamani S. Block of Na+ currents and suppression of action potentials in embryonic rat dorsal root ganglion neurons by ranolazine. Neuropharmacology 2012;62:2251-2260
27. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-269
28. Havel PJ, Valverde C. Autonomic mediation of glucagon secretion during insulin-induced hypoglycemia in rhesus monkeys. Diabetes 1996;45:960-966
29. Bagger JI, Knop FK, Holst JJ, Vilsbøll T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes Metab 2011;13:965-971
30. Sørensen H, Winzell MS, Brand CL, et al. Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes 2006;55:3463-3469
31. Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Dia-betologia 2001;44:2018-2024
32. Lee Y, Wang MY, Du XQ, Charron MJ, Linger RH. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 2011;60: 391-397
33. Engel SS, Xu L, Andryuk PJ, et al. Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM). Late-breaking abstract presented at the 71st Annual Meeting of the American Diabetes Association, 24-28 June 2011, at the San Diego Convention Center, San Diego, California
34. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 2002;290:839-843
35. Sloop KW, Cao JX, Siesky AM, et al. Hepatic and glucagon-like peptide-1 -mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 2004;113:1571-1581
36. Prince MJ, Garhyan P, Abu-Raddad EJ, et al. Short-term treatment with glucagon receptor antagonist LY2409021 effectively reduces fasting blood glucose (FBG) and HbA1c in patients with type 2 diabetes mellitus. Diabetologia 2011;54:S86
37. Yang J, MacDougall ML, McDowell MT, et al. Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes. BMC Genomics 2011; 12:281
38. Longuet C, Robledo AM, Dean ED, et al. Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. Diabetes 2013;62:1196-1205
39. Meier JJ, Lieberberg S, Korbas S, Schneider S. Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass. Am J Physiol Endocrinol Metab 2011;300:E717-E723